Lipoprotein(a): A Review of Risk Factors, Measurements, and Novel Treatment Modalities

Area of Science:

• Cardiology
• Genetics
• Pharmacology

Background:

• Lipoprotein(a) [Lp(a)] is increasingly recognized as an independent risk factor for atherosclerotic cardiovascular disease (ASCVD).
• Early studies had limitations due to less sensitive assays, but recent large-scale genetic and observational studies strongly support the Lp(a)-ASCVD link.
• Current guidelines for Lp(a) testing vary due to its uncertain role in ASCVD.

Purpose of the Study:

• To review the mechanisms by which Lp(a) contributes to atherosclerosis.
• To explore novel pharmacologic therapies in development for reducing Lp(a) levels.
• To elucidate the connection between elevated Lp(a) and cardiovascular risk.

Main Methods:

• Review of large-scale observational studies, genome-wide association studies, and Mendelian randomization studies.
• Analysis of emerging therapeutic strategies targeting mRNA translation to reduce Lp(a).
• Examination of the atherogenic mechanisms of Lp(a).

Main Results:

• Strong evidence from multiple study types supports Lp(a) as a risk factor for ASCVD.
• New therapies, including antisense oligonucleotides and small interfering RNA, are being developed to lower Lp(a).
• These therapies aim to clarify Lp(a)'s role in ASCVD and provide clinical management tools.

Conclusions:

• Lipoprotein(a) is a significant, independent risk factor for atherosclerotic cardiovascular disease.
• Novel targeted therapies hold promise for managing elevated Lp(a) and reducing cardiovascular risk.
• Further research is crucial to fully understand Lp(a)'s atherogenicity and optimize treatment strategies.